#4D MOLECULAR THERAPEUTICS IPO FULL#
#4D MOLECULAR THERAPEUTICS IPO REGISTRATION#

Financial StatusĤD’s recent financial results are somewhat atypical of a clinical stage biopharma in that they feature material collaboration and license revenue as well as the more usual R&D and G&A expenses associated with its program development.īelow are the company’s financial results for the past two and ¾ years (Audited PCAOB for full years):Īs of September 30, 2020, the company had $88.8 million in cash and $28.0 million in total liabilities. The Fabry Disease market is significantly larger and is expected to build to an annual value of $3.3 billion by 2025, growing at a forecast CAGR of 9.6% from 2018 to 2025.Īcross its pipeline, the company faces numerous competitors, from large pharma firms such as Allergan, Biogen ( BIIB), Roche ( OTCQX:RHHBY), Sanofi ( SNY), Takeda ( TAK), Vertex ( VRTX), Novartis ( NVS), Pfizer ( PFE) and numerous smaller biopharmaceutical companies. This represents a forecast CAGR (Compound Annual Growth Rate) of The United States accounted for a majority of the 7MM market demand, totaling $134 million in 2017.Ĭurrently, the market is characterized by 'support treatment regimens,' principally Luxturna, as well as potentially emerging therapies.Īs a result, the RP market has tended toward slow growth in recent years, with the hope that new players will enter the market with novel treatment options.

Market & CompetitionĪccording to a 2020 market research report by ResearchAndMarkets, the 7MM market for treatments for retinitis pigmentosa was estimated at $237 million in 2017. Investors in the firm have invested at least $175 million and include Viking Global Opportunities, Pfizer ( PFE) and Biotechnology Value Fund. The firm's lead candidate is 4D-125, which it is developing for the treatment of X-linked retinitis pigmentosa.ĤD-125 is currently in Phase 1/2 trials and management expects initial clinical data in 2021.Īdditionally, 4D is advancing 4D-110 (licensed from Roche) for the treatment of choroideremia in Phase 1 trials, for which it expects initial clinical data in 2022.īelow is the current status of the company’s drug development pipeline: Management is headed by co-founder and CEO David Kirn M.D., who was previously Executive Chairman of Ignite Immunotherapy and held senior developer positions at Onyx Pharmaceuticals and Celgene.īelow is a brief overview video of gene therapy for inherited retinal diseases: Company & TechnologyĮmeryville, California-based 4D was founded to develop its 'evolved AAV vectors' to target genetically mutated cells with reduced immunogenicity in the three areas of ophthalmology, cardiology and pulmonology. The firm is clinical stage biopharma using AAV vectors to deliver genetic therapies for various disease conditions.įDMT has achieved intriguing preclinical study results, enjoys the financial support of major pharma Pfizer and a significant collaboration relationship with Roche, and the IPO appears reasonably valued.įor life science investors with a one to two year hold time frame, the IPO is worth further consideration.

#4D MOLECULAR THERAPEUTICS IPO REGISTRATION#

4D Molecular Therapeutics ( NASDAQ: FDMT) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement.

4d molecular therapeutics ipo